GLP-1受体激动剂致药物性肝损伤的文献病例分析

打开文本图片集

中图分类号R969.3 文献标志码A 文章编号 1001-0408（2025）20-2561-05

DOI 10.6039/j.issn.1001-0408.2025.20.13

Literature case analysis of drug-induced liver injury induced by GLP-1 receptor agonists

ZHANG Menghua'， ZHU Ying1，WU Ziyang1，WANG Yanhua²，XIONG Xiangzun³，MIAO Liyan'[1.Dept.of Pharmacy，the First Affiliated Hospital of Soochow University，Jiangsu Suzhou 215006，China；2.Dept.of Pharmacy，the Second Afiliated Hospital of Kunming Medical University，Kunming 650101，China;3.Dept.of Pharmacy，Chongqing University Central Hospital （Chongqing Emergency Medical Center），Chongqing 400010，China]

ABSTRACTOBJECTIVEToinvestigate theclinicalcharacteristicsof drug-iducedliverinjury（DILI）inducedbyglucagonlikepeptide-1receptoragonists（GLP-1RAs），andtoprovideareference forsafeclinical medication.METHODS Using search terms suchas“GLP-1”“GLP-1RAs”“semaglutide”“drug-induced liver injury”，relevant studies from PubMed，Embase，the Cochrane Library，CNKI，Wanfang Dataand VIPwereretrieved.Descriptive analysiswas performedoncasesofDILIinduced by GLP-1RAs.RESULTS A total of11 studies，comprising11 patients，were included.Among them，4 were male （36.4%） and7 were female （ 63.6% ）.Patient ages ranged from17 to 64 years；5 patients（ 45.5% ）were between 5O and 65 years old. Six patients weretreatedfordiabetes，andfiveforweightlossTenpatientshadunderlyingdiseases.TheshortesttimetotheonsetofDLIwas 5daysafter medication，while thelongest wasapproximately18O days.TheDILIsinducedby GLP-1RAs weremainly hepatocellar injurytype（6cases）；severity levelsincludedsevere（3cases），moderate（6cases），and mild（2cases）. Gastrointestinal symptomsand jaundicewere themostcommon clinical manifestations.Theasociation between DILIand GLP1RAs wasasssedas“probable”in10casesand“posible”inlcase.All1lpatientsimprovedafterdrugdiscontinuationand（or） corresponding treatment.CONCLUSIONSDILI inducedby GLP-1RAs isrelativelyconcentrated inpatientsaged 50-65，witha higherincidenceinfemales.Theriskmaybefurtherincreasedinpatientswithunderlyingdiseases.Clinicaluseoftheseagents shouldenhancepharmaceuticalcare，includingidentificationof high-risk populationsandpatienteducation（especiallysymptom

recognition）.When relevant symptomsappear， the drug should be discontinued immediately，with liver-protective therapy initiated when necessary，to ensure patient safety of drug use.

KEYWORDS GLP-1 receptor agonists；drug-induced liver injury；literature case analysis；safety

胰高血糖素样肽-1受体激动剂（glucagon-likepeptide-1receptoragonists，GLP-1RAs）可通过葡萄糖浓度依赖性调节胰岛素和胰高血糖素分泌、延缓胃排空，并可通过中枢性的食欲抑制来减少进食量，从而实现降糖减重的双重效果，现已成为2型糖尿病（type2diabetes，T2DM）及肥胖症治疗的重要选择[。（剩余9768字）